Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women

Carroll, James P., Protani, Melinda, Nguyen, Linda, Cheng, Matthew E., Fay, Mike, Saleem, Mohamed, Pillay, Praga S., Walpole, Euan and Martin, Jennifer H. (2014) Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women. Medical Oncology, 31 4: 881. doi:10.1007/s12032-014-0881-z

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Carroll, James P.
Protani, Melinda
Nguyen, Linda
Cheng, Matthew E.
Fay, Mike
Saleem, Mohamed
Pillay, Praga S.
Walpole, Euan
Martin, Jennifer H.
Title Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women
Journal name Medical Oncology   Check publisher's open access policy
ISSN 1357-0560
Publication date 2014-02-19
Year available 2014
Sub-type Article (original research)
DOI 10.1007/s12032-014-0881-z
Open Access Status
Volume 31
Issue 4
Start page 881
Total pages 7
Place of publication Totowa, NJ, United States
Publisher Humana Press
Language eng
Subject 2720 Hematology
2730 Oncology
1306 Cancer Research
Abstract The purpose of this study was to compare toxicity rates and types between obese and non-obese women during adjuvant chemotherapy for breast cancer, adjusting for regimen type and received dose. We conducted a retrospective cohort study of 537 women receiving chemotherapy, initially treated between 2007 and 2010 at two tertiary hospitals in Brisbane, Australia. Demographic, chemotherapy and toxicity data were extracted from patient charts and analyzed using multivariate logistic regression. Three hundred and seventy-four women were eligible for inclusion. Obese women (body mass index (BMI) > 30 kg/m2; mean age 52.58 ± 9.49) were older than non-obese women (BMI ≤ 29.9 kg/m2; mean age 50.19 ± 11.15, P = 0.05) and had more comorbidities (P < 0.01). After adjustment for potential confounders, obesity was not statistically related to chemotherapy-related admission risk (OR 1.27; 95 % CI 0.78-2.09) or febrile neutropenia risk (OR 0.56; 95 % CI 0.28-1.21). However, obese women received chemotherapy with proportionally lower mean relative dose intensity than non-obese women (94 vs. 97 % of reference dose, P = 0.03). Eighteen (15.8 %) obese and zero non-obese women (P < 0.01) had their chemotherapy dose capped at an arbitrary body surface area. Compared with non-obese women, obese women receive different chemotherapy regimens and relatively lower chemotherapy doses. There was no significant evidence of increased toxicity among obese women with either full or adjusted chemotherapy doses. Full body surface areas-based dosing appears to be tolerated as well in obese as in lean women.
Keyword Anti-neoplastic
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2015 Collection
School of Public Health Publications
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 8 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 9 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 26 Mar 2014, 01:10:23 EST by Nyree Divitini on behalf of Health LinQ